ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

BACKGROUND: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxic chemotherapy that causes interstrand breaks (platinum-based drugs). The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide excision repair pathw...

Descripción completa

Detalles Bibliográficos
Autores principales: Baiomy, Mohamed Ali EL, El Kashef, Wagdi F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454751/
https://www.ncbi.nlm.nih.gov/pubmed/28345838
http://dx.doi.org/10.22034/APJCP.2017.18.2.507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454751/
https://www.ncbi.nlm.nih.gov/pubmed/28345838
http://dx.doi.org/10.22034/APJCP.2017.18.2.507

Ejemplares similares